• What’s True Of Mice ≠ What’s True Of Men

    As ATMPs advance, scientists are calling out the limited value of mouse models in pharmacological re-search and testing. LIfT Biosciences’ Founder and CEO Alex Blyth is a vocal proponent of organ-oid/tumoroid models.

  • Is AI/ML Bringing Medicines To Patients Faster And Cheaper?

    It is critical to move beyond simply using AI as a buzzword and instead determine if AL/ML does indeed change the discovery and clinical development process by bringing innovation to patients faster and at a lower investment.

  • Building A Successful Internal Innovation Incubator

    With so many internal incubators failing, what is the right formula for success? Leading the U.S. Digital Transformation & Innovation team for Novo Nordisk, I was on the frontlines addressing this very question.

  • Platforms To Pipelines: Part 1

    To discover why companies go about transforming themselves from technology suppliers into biotherapeutics developers, we spoke with the heads of five companies built upon novel platforms for discovery or development of new biotherapeutics, though at various stages and differences in applied strategies.

  • IP Do’s And Don’ts For Early-Stage Life Sciences Companies

    Early-stage life sciences companies typically focus their time and resources on developing their core products, positioning them for commercial success, and, if applicable, obtaining FDA approval. Intellectual property protection is often further down their list of priorities. This is a mistake.

  • Tackling Uncertainty In Drug R&D

    Can bioinformatics help biopharma companies manage their expectations and limit their risk in drug R&D? Ben Zeskind, a CEO who has built and bet his entire career on a positive answer to that question, discusses his reasons for optimism.

  • COVID Presents An Opportunity For Rural Biopharma Innovation

    During the COVID pandemic, skilled workers began leaving urban centers (or the workforce altogether) to improve their quality of life and get some literal and figurative distance. How do we ensure that innovation follows?

  • Involve Patients In Product Development … From The Beginning

    When bringing new therapies to market, it’s no longer just about efficacy and safety data when trying to gain regulatory approval. Nowadays, input from patients throughout the development of medical products is more important than ever.

  • How Small Biotechs Can Implement Pharmacovigilance Systems

    Learnings on how to implement drug safety protocols effectively — both time-wise and cost-wise

  • Inside The Planning Of Audentes' Future Manufacturing Facility

    A Q&A regarding Audentes Therapeutics’ Sanford, NC future facility, which will manufacture the company’s portfolio of adeno-associated virus (AAV)-based gene therapies aimed at targeting serious rare neuromuscular diseases.